Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing  by Neggers, Jasper E. et al.
Chemistry & Biology
ResourceIdentifying Drug-Target Selectivity
of Small-Molecule CRM1/XPO1 Inhibitors
by CRISPR/Cas9 Genome Editing
Jasper E. Neggers,1 Thomas Vercruysse,1 Maarten Jacquemyn,1 Els Vanstreels,1 Erkan Baloglu,2 Sharon Shacham,2
Marsha Crochiere,2 Yosef Landesman,2 and Dirk Daelemans1,*
1Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research,
KU Leuven-University of Leuven, 3000 Leuven, Belgium
2Karyopharm Therapeutics, Newton, MA 02459, USA
*Correspondence: dirk.daelemans@rega.kuleuven.be
http://dx.doi.org/10.1016/j.chembiol.2014.11.015SUMMARY
Validation of drug-target interaction is essential in
drug discovery and development. The ultimate proof
for drug-target validation requires the introduction
of mutations that confer resistance in cells, an
approach that is not straightforward in mammalian
cells. Using CRISPR/Cas9 genome editing, we
show that a homozygous genomic C528S mutation
in the XPO1 gene confers cells with resistance to
selinexor (KPT-330). Selinexor is an orally bioavail-
able inhibitor of exportin-1 (CRM1/XPO1) with potent
anticancer activity and is currently under evaluation
in human clinical trials. Mutant cells were resistant
to the induction of cytotoxicity, apoptosis, cell cycle
arrest, and inhibition of XPO1 function, including
direct binding of the drug to XPO1. These results vali-
date XPO1 as the prime target of selinexor in cells
and identify the selectivity of this drug toward the
cysteine 528 residue of XPO1. Our findings demon-
strate that CRISPR/Cas9 genome editing enables
drug-target validation and drug-target selectivity
studies in cancer cells.
INTRODUCTION
Human exportin-1 (XPO1), also known as chromosome region
maintenance 1 protein (CRM1), is a key nuclear-cytoplasmic
transport protein or karyopherin that exports a broad range of
different cargo proteins out of the cell’s nucleus (Fornerod
et al., 1997; Fukuda et al., 1997; Neville et al., 1997; Ossareh-
Nazari et al., 1997; Stade et al., 1997). These cargo proteins
include tumor suppressor and growth regulatory-related pro-
teins; therefore, correct XPO1 function is key to normal cell ho-
meostasis (Kau et al., 2004; Turner et al., 2012; Xu et al., 2010).
In recent years, overexpression or dysfunction of XPO1 has
commonly been observed in different types of cancer and has
been correlated with poor prognosis and resistance to therapy
(Shen et al., 2009; van der Watt et al., 2009; Yao et al., 2009).
Indeed, alterations in XPO1 expression levels may cause sub-Chemistry & Biology 22, 107cellular mislocalization of tumor suppressor proteins and cell
cycle regulators, resulting in uncontrolled cell growth and carci-
nogenesis (Aloisi et al., 2006; Falini et al., 2006; Zhang and
Xiong, 2001). Therefore, XPO1 is considered an anticancer
target. Recently, N-azolylacrylate small-molecule inhibitors of
the XPO1-mediated nuclear export (Daelemans et al., 2002;
Van Neck et al., 2008) were rationally optimized in silico (Kalid
et al., 2012) based on the XPO1 crystal structure (Dong et al.,
2009; Monecke et al., 2009). These improved small-molecule
inhibitors of nuclear export, called SINE, effectively demon-
strate potent activity against multiple types of cancer and
have been shown to induce apoptosis and to abolish cancer
growth in various in vitro as well as in vivo models of cancer
(Cheng et al., 2014; Etchin et al., 2013a, 2013b; Inoue et al.,
2013; Kojima et al., 2013; Lapalombella et al., 2012; Rangana-
than et al., 2012; Tai et al., 2014; Walker et al., 2013; Zhang
et al., 2013). Importantly, selinexor (KPT-330), the clinical candi-
date of these SINE molecules currently enrolling for phase 2
clinical studies, demonstrated high response rates as a single
agent in phase 1 trials for heavily pretreated, relapsed, and re-
fractory hematological and solid tumor malignancies in humans
(Chen et al., 2014; Mahaseth et al., 2014). Preclinical analogs of
this drug inhibit the formation of XPO1-cargo complex in vitro,
and cocrystal structures with XPO1 protein have demonstrated
their binding into the cargo-binding pocket of XPO1 (Etchin
et al., 2013b; Lapalombella et al., 2012). The binding is pro-
posed to involve an irreversible Michael addition type interac-
tion of their acrylate moiety with the cysteine 528 residue of
XPO1 (Lapalombella et al., 2012; Van Neck et al., 2008). These
SINE compounds have been shown to cause an accumulation
of tumor-suppressor proteins in the nucleus of treated cells,
which is correlated with the induction of cell cycle arrest and
apoptosis. However, the specificity of the drug-target interac-
tion in cancer cells is not validated. Indeed, it has not been
directly demonstrated in cells that the anticancer activity of
SINE is selectively caused by inhibition of XPO1 function and
not by other mechanisms resulting in or adding to the observed
anticancer activity.
Drug-target validation is an essential step in drug discovery.
While identification of drug-resistance mutations is regarded as
the gold standard for target confirmation, further validation of
drug-target interaction requires the resistance mutation to be
introduced into the WT background, a method widely used in–116, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 107
Figure 1. Generation of a Mutant XPO1C528S
Cell Line Using CRISPR/Cas9 Genome
Editing and Homologous Recombination
(A) A schematic presentation of the two SINE
compounds KPT-185 and KPT-330.
(B) Schematic overview of the CRISPR/Cas9-
induced homologous recombination of human
XPO1. Exons are represented by open thick
arrows. The blue arrow indicates the sgRNA
target site, and small arrowheads beneath the
exons indicate forward and reverse PCR A or
sequencing primers B. The site of recombination is
enlarged, and the location of the double strand
break (scissors and arrow) is shown. Both the WT
XPO1 and donor mutant template sequences are
shown at the bottom (magenta, PAM motif; bold,
cysteine 528 codon; red, template mutations;
underlined, sgRNA sequence).
(C) Sequencing chromatogram of genomic DNA
of the XPO1 region around the targeted cysteine
codon (in bold) from XPO1C528S cells (clone 6). See
also Figure S1 and Table S1.
(D) Partial protein sequence of XPO1 in WT and
mutant XPO1C528S cells (clone 6). Residue 528 of
XPO1 is shown in bold.
(E) Sequencing chromatogram of the mRNA
from XPO1C528S cells (clone 6) in the XPO1 region
around the targeted cysteine codon.
(F) Visualization of XPO1 protein expression in WT
and mutant XPO1C528S cells (clone 6) by immu-
noblot with b-tubulin as loading control.
(G) Relative comparison of XPO1 mRNA expres-
sion levels quantified with a probe specific
to exon 2 of XPO1 (unpaired student’s t test
p value, <0.0001). GAPDH and b-actin were used
as internal controls.
(H) Relative comparison of mean XPO1 protein
expression in WT and XPO1C528S cells (clone 6)
asmeasured by immunofluorescence staining and
quantified by confocal fluorescence microscopy
(unpaired student’s t test p value, <0.0001). Error
bars indicate the 95% confidence interval.
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advent of the CRISPR/Cas9 genome editing technique (Cho
et al., 2013; Jinek et al., 2012; Mali et al., 2013), this approach
was not straightforward in mammalian cells. Very recently, proof
of concept for drug validation in human cells has been shown
based on resistance selection and genome sequencing in com-
bination with CRISPR/Cas9 genome editing (Kasap et al., 2014;
Smurnyy et al., 2014). Although drug resistance against selinexor
has not been raised so far, we reasoned that genomic mutation
of the cysteine 528 residue in XPO1 may cause resistance. In
higher eukaryotes, however, this residue is very well conserved
(Gu¨ttler et al., 2010; Nguyen et al., 2012), raising the question
of whether a genomic mutation of this cysteine 528 residue is
even possible in human cells. In lower eukaryotes, variations of
this cysteine residue are rarely observed. For example, Saccha-
romyces cerevisiae and Aspergillus nidulans both contain a
threonine residue at this position, while a mutant strain of
Saccharomyces pombe has been reported to carry a serine res-
idue (Kudo et al., 1999).
In this study, we used CRISPR/Cas9 genome editing in com-
bination with homology-directed repair (HDR) to introduce a sin-108 Chemistry & Biology 22, 107–116, January 22, 2015 ª2015 Elsevgle XPO1 C528S mutation in acute T cell leukemia Jurkat cells.
This mutant cell line was used to validate XPO1 as the specific
target for the SINE compounds, including the clinical stage
XPO1 inhibitor selinexor, and to assess the selectivity of the
drug for the cysteine 528 residue in the hydrophobic cargo-bind-
ing groove of XPO1.
RESULTS
Generation of a Homozygous XPO1 C528S Mutant
Jurkat Cell Line
We have employed CRIPSR/Cas9 genome editing to alter the
TGT codon, encoding for the cysteine 528 residue in exon 14
of the XPO1 gene, of T-ALL Jurkat cells via homologous recom-
bination. These cells have been demonstrated to be highly sen-
sitive to the SINE compounds, including KPT-185 and KPT-330
(Figure 1A) (Etchin et al., 2013a; Etchin et al., 2013b). A plasmid
expressing Cas9 protein fused to a nuclear localization signal
sequence was cotransfected with a plasmid expressing a
23-bp guide RNA (sgRNA) and with a 135 base long single-
stranded oligodeoxynucleotide repair donor template containingier Ltd All rights reserved
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duce a serine residue at position 528 in the hydrophobic cargo-
binding pocket of XPO1 (Figure 1B). We hypothesized that if
the C528S mutation in XPO1 per se is not lethal Jurkat
XPO1C528S mutants may be insensitive to KPT-185, the preclin-
ical analog of selinexor (KPT-330). Therefore, 2 days following
transfection, transfected cells were treated with 100 nM of
KPT-185. Although very high cell toxicity was observed within
3 days, some cells survived treatment and were cultured further
and subsequently distributed to 96-well plates to obtain single-
cell colonies. Genomic DNA from ten of these single-cell derived
colonies was extracted and analyzed using PCR and Sanger
sequencing. The majority of these colonies only integrated the
desired missense mutation at exon 14 in one of the two XPO1 al-
leles, while the other allele contained the completeWT sequence
(two of ten), the WT sequence with silent mutations but not the
desired missense mutation (two of ten) or showed an insertion
(three of ten) or a deletion (one of ten) caused by inefficient
nonhomologous end joining (NHEJ) (Table S1 available online).
The two remaining clones (two of ten) appeared to have effec-
tively integrated the C528Smutation at both alleles, as observed
in the sequencing chromatogram of the genomic DNA (Figures
1C, 1D, and S1) and of themRNA (Figure 1E). All sequences con-
taining the C528S mutation also contained the three additional
silent mutations, effectively ruling out spontaneous generation
of resistance mutations due to selective pressure by KPT-185.
Both the heterozygous and homozygous XPO1C528S mutant
clones were viable and have been cultured for several months.
One of the two homozygous clones (clone 6) was selected and
used for all further experiments. This clone showed a slightly
higher XPO1 expression level compared with WT when analyzed
by immunoblot (Figure 1F), quantitative RT-PCR (Figure 1G),
and quantitative confocal immunofluorescence microscopy
(Figure 1H).
C528SMutationConfers Resistance to the SINEClass of
XPO1 Inhibitors
The homozygous mutant XPO1C528S cell line (clone 6) that we
have generated is a powerful tool to directly investigate and vali-
date XPO1 as the key target for the SINE compounds KPT-185
and the clinical KPT-330 (selinexor) in cancer cells. Therefore,
the cytotoxic effects of KPT-185 and KPT-330 onWT andmutant
XPO1C528S Jurkat cells were assessed. Both compounds were
highly cytotoxic to WT Jurkat cells in the low nanomolar range
(IC50 of 20.8 ± 4.3 and 41.0 ± 6.4 nM, respectively), consistent
with Etchin et al. (2013a), while the XPO1C528S mutant cells
were resistant up to micromolar concentrations to both drugs
(IC50 of 7.2 ± 1.2 and 10.3 ± 2.3 mM, respectively) (Figure 2A).
Similar results were obtained with the other obtained homozy-
gous mutant clone (Figure S2). The XPO1 C528S mutation
conferred >250-fold resistance to KPT-185 and KPT-330. As
these drugs have been shown to rapidly promote apoptosis in
cancer cell lines in vitro (Etchin et al., 2013a; 2013b; Inoue
et al., 2013; Kojima et al., 2013; Lapalombella et al., 2012; Ran-
ganathan et al., 2012; Tai et al., 2014; Walker et al., 2013; Zhang
et al., 2013), as well as in human trials (Chen et al., 2014), we
wanted to confirm this resistance by investigating the apoptotic
effects of KPT-185 and KPT-330 on the mutant cells. Resistance
to apoptosis of mutant XPO1C528S cells treated with micromolarChemistry & Biology 22, 107concentrations was confirmed by annexin V/PI flow cytometry,
while only low nanomolar concentrations of compound were
sufficient to induce apoptosis in WT Jurkat cells (Figures 2B
and 2C). The induction of apoptosis and cell death in WT
cells by both compounds is caspase dependent, as it was
prevented all together by the addition of the pancaspase
apoptosis inhibitor Q-VD-OPh (Figure 2C). Only at extreme
high concentrations of both compounds (>5 mM) the fraction of
dead and apoptotic mutant cells appeared to increase slightly
(Figure 2C). Resistance to apoptosis of the mutant cell line was
further confirmed by visualization of caspase-3 activation and
cleavage of the caspase-3 substrate PARP by western blotting
(Figure 2D).
Treatment with XPO1 inhibitors is known to arrest cell-cycle
progression (Etchin et al., 2013a, 2013b; Inoue et al., 2013;
Kojima et al., 2013; Ranganathan et al., 2012; Tai et al., 2014;
Zhang et al., 2013). To further validate that the cytotoxic effects
induced by the compounds are caused by the inhibition of
XPO1, we next assessed the impact of the C528S mutation
on the effect of both drugs on cell cycle progression (Figures
3A and 3B). Treatment of WT cells resulted in a G1/G0 cell
cycle arrest with lowered S and G2 phases after 24 hr of incu-
bation with low concentrations of the compounds (Figure 3B),
which is in line with previous observations. An increase in
sub-G1 apoptotic WT cells was also observed and becomes
even more pronounced at higher compound concentrations,
consistent with the levels of Annexin V staining. In contrast,
the mutant XPO1C528S cells showed no marked differences in
the cell cycle profile as compared with the negative control
condition at the same or even micromolar concentrations
(Figure 3B).
C528S Mutation Rescues XPO1 Function in the
Presence of SINE and Prevents the Direct Binding of
SINE to the XPO1 Protein
To further confirm that the C528S mutation rescues XPO1 from
inhibition by the drugs, we assessed the effect of the compounds
on the nuclear export function of the mutant XPO1C528S. There-
fore, the subcellular localization of the RanBP1 cargo-
protein was visualized in the presence of the compounds by
confocal fluorescence microscopy. In the absence of XPO1 in-
hibitor, RanBP1 is found in the cytoplasm of bothWT andmutant
cells. Within 3 hr after the addition of drug, RanBP1 accumulated
in the nucleus ofWT cells, as caused by inhibition of XPO1-medi-
ated nuclear export (Figure 3C, left panels). Interestingly, the
SINE compounds were unable to inhibit the nuclear export of
RanBP1 in the mutant XPO1C528S cells (Figure 3C, right panels),
suggesting that mutant XPO1C528S is active and can bind cargo
proteins. Indeed, it has been previously shown in vitro that
mutant XPO1C528S interacts with cargos (Gu¨ttler et al., 2010).
In addition a cysteine to serine substitution has been found in
mutants of the yeast S. pombe, which is dependent on functional
XPO1 protein. To further confirm the mutant XPO1’s ability to
interact with cargo in human cells and thus overcome inhibition
by the compounds, we assessed XPO1-cargo binding in cells
by means of a cotransfection assay with fluorescently tagged
XPO1 and the prototype XPO1 cargo protein HIV-1 Rev. HeLa
cells were cotransfected with plasmids expressing Rev fused
to the blue fluorescent protein (BFP) and either WT XPO1 or–116, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 109
Figure 2. XPO1C528S Mutant Cells Are Resistant to KPT-185 and KPT-330
(A) Cellular viability ofWT andmutant XPO1C528S Jurkat cells with increasing concentrations of KPT-185 or KPT-330 (selinexor). Data points represent the average
of all data collected over at least five independent experiments performed in duplicate; error bars indicate SD. See also Figure S2.
(B) Dot plot analysis of apoptosis (Annexin V) and cell death (PI) in WT and mutant XPO1C528S Jurkat cells after 12 hr of treatment with various concentrations of
KPT-330.
(C) Overview of apoptosis and cell death profiles in WT and mutant XPO1C528S Jurkat cells determined by Annexin V and PI staining after 12 hr treatment with
carrier (DMSO) or compound (KPT-330 and KPT-185). Stacked columns represent 100%. Where indicated, the pancaspase apoptosis inhibitor Q-VD-OPh was
added in addition to the highest concentration of compound. Values represent averages of all data collected over three independent experiments, and error bars
indicate the SD. The relative amount of apoptotic, dead or living cells in each condition was compared with the respective fraction of the DMSO control (unpaired
student’s t test *p value, <0.05).
(D) Detection of caspase-3 and PARP cleavage in WT and mutant XPO1C528S Jurkat cells after 16 hr treatment with various concentrations of KPT-185 and
KPT-330 or DMSO. Where indicated, the pancaspase inhibitor Q-VD-OPh was added in addition to the highest concentration of compound.
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(Figure 3D) (Daelemans et al., 2005). The Rev-BFP protein is
localized to the nucleoli of the cells, while XPO1 is mainly found110 Chemistry & Biology 22, 107–116, January 22, 2015 ª2015 Elsevat the nuclear membrane and throughout the nucleus, but is
generally excluded from the nucleoli (Figure 3Da and Db).
When both proteins are coexpressed, a significant portion ofier Ltd All rights reserved
Figure 3. XPO1C528S Substitution Confers Resistance to Cell Cycle Arrest, Inhibition of XPO1 Function, andDirect Binding of theDrug to XPO1
(A) Visualization by histogram of the cell cycle profile in WT and mutant XPO1C528S Jurkat cells as determined by staining with PI after 24 hr treatment with
KPT-330 or DMSO. The percentage distribution of cells in a specific phase of the cell cycle is shown in the top right corner.
(B) Overview of the various cell cycle profiles as determined by PI staining in WT and XPO1C528S Jurkat cells after 24 hr treatment with carrier (DMSO) or various
concentrations of KPT-185 or KPT-330. Stacked columns represent 100%. Values represent the average of all data collected over five independent experiments,
and the error bars indicate the SD of all data points collected. The fraction of each cell cycle phase in each condition was compared with the DMSO-treated
control condition (unpaired student’s t test, *p < 0.05).
(C) Immunofluorescence analysis of RanBP1 cargo (green) inWT andmutant XPO1C528S Jurkat cells after 3 hr treatment with DMSO or 1 mMcompound (KPT-185
or KPT-330). Cell nuclei are counterstained with DAPI (blue). DIC, differential interference contrast.
(D) Confocal fluorescence microscopy analysis of the colocalization of WT XPO1-YFP or mutant XPO1C528S-YFP (yellow) with Rev-BFP (blue) in HeLa cells.
Rev-BFP localizes in the nucleoli of the cells (a, left panel). WT XPO1-YFP or mutant XPO1C528S-YFP are mainly found within the nucleus and at the nuclear rim,
but are generally excluded from the nucleoli (b, middle). Coexpression of Rev-BFP with XPO1-YFP or XPO1C528S-YFP results in a colocalization of both WT or
mutant XPO1-YFP protein with Rev-BFP in the nucleoli (c). One hour after the addition of 1 mMKPT-330 the colocalization of XPO1-YFP or XPO1C528S-YFP with
Rev-BFP was visualized (d). DIC, differential interference contrast.
(E) Schematic presentation of KPT-9058, a biotinylated analog of KPT-276. KPT-276 is another member of the SINE class of XPO1 inhibitors and a structural
analog of KPT-185 and KPT-330. The biotin moiety is shown in light gray.
(F) Pull down of XPO1 protein with KPT-9058. Cells were incubated with DMSO or 1 mM of KPT-9058 for 1.5 hr and subsequently streptavidin affinity
chromatography was used to pull down XPO1 protein out of the WT or mutant XPO1C528S cells.
See also Figure S3.
Chemistry & Biology
Drug-Target Validation in Mammalian CellsWT or mutant XPO1-YFP protein is colocalized with Rev-BFP in
the nucleoli (Figure 3Dc) (Costes et al., 2004). It must be noted
that colocalization of two proteins inside cells is generally not aChemistry & Biology 22, 107direct proof of interaction. However, as the XPO1 protein is
excluded from the nucleoli in the absence of Rev and only reloc-
alizes to the nucleoli when Rev is present, together with the fact–116, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 111
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the prototype cargo for XPO1, is well established in the literature,
we believe that the observed colocalization is the result of an
interaction between XPO1 and Rev. An additional argument is
that the colocalization with WT XPO1 is disrupted upon treat-
ment with KPT-330 (Figure 3D), which is in agreement with
biochemical interaction assays where preclinical analogs of
KPT-330 have been shown to disrupt the direct interaction be-
tween WT XPO1 and the Rev nuclear export signal sequence
(Etchin et al., 2013b; Lapalombella et al., 2012). Upon treatment
with KPT-330, the interaction between Rev-BFP and mutant
XPO1C528S-YFP is not affected by KPT-330, demonstrating
that the C528S substitution confers resistance to the drug with
respect to cargo binding.
Next the interaction of SINE compounds with WT XPO1 or
mutant XPO1C528S cellular protein was assessed. For this pur-
pose, WT and mutant cells were treated with 1 mM biotinylated
analog of KPT-276 (KPT-9058) (Figure 3E) to pull down XPO1
protein. KPT-276 is another SINE compound and a structural
analog of KPT-330 and KPT-185 carrying the same acrylate
warhead. It shows similar anticancer activity as KPT-185 and
KPT-330 (Ranganathan et al., 2012; Tai et al., 2014; Zhang
et al., 2013). Similar to KPT-185 and KPT-330, this biotinylated
derivative induced potent cytotoxic effects on WT Jurkat cells
(IC50 of 187.25 ± 9.77 nM), while it was inactive against the
XPO1C528S mutant cells (IC50 of 18.46 ± 2.30 mM) (Figure S3).
Streptavidin affinity chromatography was used to isolate the
compound from the cell lysate, and coprecipitated XPO1
protein was detected by western blot analysis (Figure 3F). In
contrast to WT XPO1, KPT-9058 did not interact with the
mutant XPO1C528S protein of the resistant cells, further strength-
ening the finding that the C528S substitution confers resistance
to SINE.
Altogether these results validate XPO1 as the target for the
SINE compounds and more specifically pinpoint the C528
residue as a highly selective anchor point for these drugs.
DISCUSSION
Drug-target validation is an indispensable step in drug discov-
ery. While identification of drug-resistance mutations is re-
garded as the ultimate proof for target confirmation, further
validation of drug-target interaction requires the resistance
mutation to be introduced into the WT background. This
method is widely used in prokaryotes, lower eukaryotes, and
viruses but has not been straightforward in mammalian cells.
Selinexor (KPT-330) is the clinical candidate of a promising
class of anticancer drugs (SINE) targeting XPO1 and yet
displayed promising preliminary results (Chen et al., 2014;
Kuruvilla et al., 2013; Mahaseth et al., 2014). Although, pre-
vious in vitro and structural studies have demonstrated the
interaction of these molecules with XPO1, and the accumula-
tion of tumor suppressor proteins in the nucleus of treated
cells is correlated with the induction of apoptosis; the selec-
tivity of selinexor for XPO1 as well as the causality between
the inhibition of XPO1 and its anticancer activity has not been
directly validated in cells. Here we applied CRISPR/Cas9
genome editing to validate the selinexor-XPO1 interaction in
cancer cells.112 Chemistry & Biology 22, 107–116, January 22, 2015 ª2015 ElsevUsing CRSIPR/Cas9 genome editing combined with HDR, we
obtained a homozygous Jurkat T-ALL cell line containing a
C528S point mutation in XPO1. We then evaluated the effect of
selinexor on cell viability, apoptosis, and cell cycle progression,
as these parameters were found to be greatly affected by this
drug in both preclinical models of cancer as well as in human
trials. The mutant XPO1C528S cells were highly resistant to seli-
nexor when compared with WT on all of these parameters and
the C528S mutation conferred >250-fold resistance to selinexor.
Although we observed a slight increased XPO1 expression in the
mutant cell line, we believe this does not significantly contribute
to the observed >250-fold resistance. Concomitantly, selinexor
did not induce cell cycle arrest nor inhibit XPO1-mediated cargo
export in mutant cells. However, at very high concentrations, a
slight increase in apoptotic cells could be observed. By using a
biotinylated analog, we could demonstrate the direct binding
of this class of compounds to WT cellular XPO1 protein while
the single C528S substitution in the mutant cells conferred resis-
tance to this drug-target interaction. These results demonstrate
that the anticancer activity of selinexor is directly caused by a se-
lective inhibition of the XPO1 function and pinpoint the unique
selectivity of this class of XPO1 inhibitors for the cysteine 528
residue of XPO1 in human cells.
In addition, our findings illustrate the general utility of intro-
ducing point mutations in the genome of mammalian cells to
validate drug-target interaction and investigate target selectivity.
Two studies very recently provided proof of concept for CRISPR/
Cas9 combined with sequencing of drug-resistant clones in
drug-target validation (Kasap et al., 2014; Smurnyy et al.,
2014). Our study shows that the CRISPR/Cas9 approach can
be applied to validate drug-target interaction without genome
sequencing data of existing drug-resistant cell lines, as these
do not exist for the current XPO1 inhibitors. Consequently, it
allows for the determination of target selectivity of drugs for
which drug-resistant clones are nonexistent and therefore
already provides predictive information on the resistance profile
that could arise against the drugs. Furthermore, we managed to
obtain homozygousmutants demonstrating proof of principle for
CRISPR/Cas9 genome editing to study recessive drug-resis-
tance mutations.
Although the XPO1 C528 residue is well conserved among
higher eukaryotes (Gu¨ttler et al., 2010; Nguyen et al., 2012), we
were able to introduce the C528S point mutation in both alleles
of Jurkat cells and generate homozygous XPO1C528S mutant
cells. This demonstrates that the cysteine residue inside the
hydrophobic cargo-binding groove of XPO1 can be effectively
mutated in higher eukaryotes. We have chosen to introduce a
serine residue because of its chemical similarity to cysteine
and because this mutation has been found in yeast strains
(Kudo et al., 1999), but other amino acid substitutions might be
envisaged. Although the CRISPR/Cas9 technology is sometimes
criticized for its off-target genome alterations (Fu et al., 2013;
Hsu et al., 2013; Pattanayak et al., 2013), we did not screen for
possible off-target mutations induced by the CRISPR/Cas9
technology. We believe that this is not a major limitation as the
guiding RNA was optimized to limit off-target interactions.
BLAST search indicated that one sequence contained two mis-
matches compared with targeted sequence, but these mis-
matches were located close to the PAM motif lowering theier Ltd All rights reserved
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the XPO1 gene, all other retrieved gene sequences contained
at least threemismatchmutationswhen comparedwith the guid-
ing RNA. Out of the ten clones that we selected, two effectively
integrated the desiredmutations in both alleles of XPO1 resulting
in homozygous mutant cells, while the remaining eight clones
appeared to be heterozygous for the desired mutations. These
remaining clones either contained a WT allele (four of ten) or a
dysfunctional indel containing allele as caused by inefficient
NHEJ (four of ten) (Jinek et al., 2012; Mali et al., 2013). This
observed distribution is explained by the fact that the recombi-
nation of only one of the XPO1 alleles was sufficient to provide
resistance to KPT-185.
Although HDR is generally inefficient, we managed to obtain
two homozygous clones relatively easy. This might be explained
by the enrichment of mutated clones by drug-selective pres-
sure in combination with a modified transfection protocol, in
which we retransfected the cells 24 hr after the initial transfec-
tion a second time with only repair donor template. We specu-
lated that the single-stranded repair donor oligonucleotide is
degraded quickly inside the cell. This would result in low con-
centrations of the oligonucleotide at the time the Cas9 endonu-
clease protein and the appropriate targeting RNA are effectively
expressed and present in the cells. Thus, we reasoned that addi-
tional delivery of the donor repair template after the first trans-
fection might increase the chance of successful recombination.
We have established a homozygous mutant cell line as tool to
unambiguously validate the SINE and selinexor-XPO1 interac-
tion inside the living cell and to assess the drug-target selectivity
in cells. At the same time, this cell line may have other important
implications. First, it could form the basis for the identification of
reversible noncovalent XPO1 inhibitors. Moreover, there is an
increasing body of literature reporting on the overexpression
and dysfunction of XPO1 in cancer. This cell line therefore opens
unique opportunities, as it is a powerful tool to study the role of
the cysteine 528 in the function and regulation of XPO1 in the
cell and in cancer. Cysteines are known to be susceptible to
posttranslational modification that impact protein function
(Gould et al., 2013; Hess et al., 2005; Lo Conte and Carroll,
2013; Smotrys and Linder, 2004), suggesting a possible role
for this cysteine 528 residue in XPO1 function and/or regulation.
In this context, S-nitrosylation has been suggested to regulate
XPO1 (Wang et al., 2009).
In summary, this study illustrates the utility of genome editing
in mammalian cells by the CRISPR/Cas9 technology for drug-
target validation and target selectivity determination of anti-
cancer drugs. The genomic XPO1 C528S mutation conferred
resistance to selinexor validating XPO1 as the prime target
of selinexor and demonstrating the unique selectivity of the
drug for the target in cells. Moreover, this homozygous
XPO1C528S mutant cell line may allow the identification of nonco-
valent XPO1 inhibitors and also opens opportunities for the
further investigation of the role of cysteine 528 in the regulation
of XPO1 function.
SIGNIFICANCE
In this work we reached the so-called gold standard proof
for drug-target validation in human cells by introducing aChemistry & Biology 22, 107genomicmutation in the XPO1 gene of cancer cells that con-
fers resistance to the SINE compound selinexor (KPT-330),
the clinical candidate of a class of small molecule inhibitors
of nuclear export. Exportin-1 (XPO1/CRM1) is the key nu-
clear exporter for a broad range of cargo-proteins involved
in cellular transcription, growth regulation, and tumor sup-
pression and is considered a new therapeutic anticancer
target. We applied CRISPR/Cas9 genome editing in combi-
nation with HDR to introduce a C528S mutation in XPO1 of
acute leukemia T cells and succeeded in generating amono-
clonal homozygous mutant cell line. The C528S mutation
confers resistance to selinexor validating XPO1 as the prime
target for selinexor in cancer cells. These results determine
the selectivity of selinexor for its target inside living cells.We
hereby also illustrate the general applicability of genome ed-
iting in mammalian cells by CRISPR/Cas9 for drug-target
validation and target selectivity determination of anticancer
drugs and show feasibility of this technique for the study of
recessive drug-resistance mutations. In addition, the gener-
ation of a viable homozygous mutant XPO1 C528S cell line is
quite unique since in higher eukaryotes the XPO1 C528 res-
idue is well conserved. The generated cell line is therefore a
powerful tool that opens opportunities to study the role of
the cysteine 528 residue in the function and regulation of
XPO1 in the higher eukaryotic cell.
EXPERIMENTAL PROCEDURES
Cell Culture
T-ALL Jurkat Clone E6-1 cells were obtained directly from the American Type
Culture Collection and cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS) and 200 mg/ml gentamicin (Gibco, Life Technol-
ogies). Cells were grown and maintained in T75 flasks (TPP) at a cell density
between 300,000 and 1,000,000 cells/ml.
Transfection by Electroporation
Jurkat cells were transfected with the Neon Transfection system (Invitrogen,
Life Technologies). Briefly, cells were resuspended in Buffer R (Invitrogen,
Life Technologies) at 2 3 107 cells per ml. Purified and highly concentrated
DNA plasmids and the donor ss oligonucleotide (0.5–2 mg per construct)
were electroporated with the following settings: 1,325 V, 10 ms, and three
pulses. Following electroporation, cells were immediately plated in 1 ml pre-
warmed antibiotic free and 10% FBS-supplemented RPMI 1640 Medium
(Gibco, Life Technologies) in a 24-well plate. The next day cells were harvested
and again transfected by electroporation with only the donor ss oligonucleo-
tide and immediately plated in 1 ml of antibiotic free and 10% FBS-supple-
mented RPMI 1640 Medium (Gibco, Life Technologies) in a 24-well plate. After
2 days the medium was refreshed, and KPT-185 was added to a final concen-
tration of 100 nM. Cells were thenmaintained and grown in the presence of the
compound for a period of 1 week following standard guidelines. After this
period, surviving cells were washed, harvested, and plated in 96-well plates
at a density of 0.5 cells per well in order to grow single cell colonies (mono-
clonal clones).
DNA Constructs
The Cas9 expression construct, CMV-Cas9-NLS-HA-linker, and the optimized
sgRNA construct targeting XPO1 at the Cys528 coding region were obtained
from ToolGen/Labomics. The sgRNA was located behind an U6 promotor and
contained the following targeting sequence: 50-GGATTATGTGAACAGAAAA
GAGG-30 (bold indicates the NGG protospacer adjacent motif).
The oligonucleotide used for homologous recombination consisted of a 135-
base single-stranded oligodeoxynucleotide (ssODN) molecule containing two
outer arms (50–60 bp) homologous to the endogenous XPO1 genomic region
flanking the exon coding for cysteine 528 of XPO1 and was synthesized–116, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 113
Chemistry & Biology
Drug-Target Validation in Mammalian Cellsby Integrated DNA Technologies (IDT). The oligonucleotide contained two point
mutationsat theCys528coding triplet toprovide the template for theCys528Ser
mutation as well as three silent mutations to prevent Cas9-mediated cleavage
of the mutated allele. It consisted of the following sequence: 50-GCTAAATAAG
TATTATGTTGTTACAATAAATAATACAAATTTGTCTTATTTACAGGATCTATTA
GGATTATCAGAACAGAAgcGcGGCAAAGATAATAAAGCTATTATTGCATCA
AATATCATGTACATAGTAGG-30 (bold indicates the Cys528Ser missense mu-
tation, lowercase indicates additional silent mutations).
DNA Extraction and Sequencing
Genomic DNA was extracted using the QiaGen Blood & Cell Culture DNA Mini
kit according to themanufacturer’s instructions. The target site (DNA sequence
around the XPO1 C528S mutation site) was amplified by PCR with primers
(forward: 50-TCTGCCTCTCCGTTGCTTTC, reverse: 50-CCAATCATGTACCCC
ACAGCT) targeting the exonic DNA of human XPO1. Following PCR, the prod-
ucts were sequenced by Sanger Sequencing in an ABI Prism 3130xL Gene
Analyzer using a forward and reverse primer (50-TGTGTTGGGCAATAGGCTCC
and 50-GGCATTTTTGGGCTATTTTAATGAAA, respectively).
mRNA Extraction and Sequencing
mRNAwasextractedusing theOligotexDirectmRNAMini Kit (QIAGEN) accord-
ing to themanufacturer’s instructions.DNAwas then degradedusing theDNase
I kit (Life Technologies). The XPO1 mRNA was amplified by SuperScript III
reverse transcriptase PCR (Life Technologies) with primers (forward: 50- ATAA
GCTAGCATGCCAGCAATTATGACAATG, reverse: 50- ATTCCAGAAGAAATG
TGTGATGGATCCTTAT) targeting the exonic DNA of human XPO1. Following
PCR, the products were sequenced by Sanger Sequencing in an ABI Prism
3130xL Gene Analyzer using a forward and reverse primer (50-TGTGTTG
GGCAATAGGCTCC, 50-GGCATTTTTGGGCTATTTTAATGAAA, respectively).
RNA Extraction and Quantitative PCR
Total RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN)
according to the manufacturer’s instructions. Quantitative RT-PCR was
performed on the mRNA using the Express One-Step SuperScript qRT-PCR
Kit (Invitrogen) with Prime Time qPCR probes (IDT) against mRNA of
XPO1 exon 9–10 (Hs.PT.58.4000376), mRNA of XPO1 exon 23–25
(Hs.PT.58.288478), mRNA of b-actin exon 1–2 (Hs.PT.39a.22214847), and
mRNA of GAPDH exon 2–3 (Hs.PT.39a.22214836) on the 7500 Fast Real-
Time PCR System (Applied Biosystems). All assays were performed with three
biological replicates and three technical replicates, and comparative
computed tomography was used to analyze the results with b-actin and
GAPDH serving as internal controls. Statistical significance was determined
with an unpaired two-tailed Student’s t test.
Cell Viability, Cell Cycle, and Apoptosis Analysis
Three-day cell viability assayswere performedby plating Jurkat cells to 96-well
plates containing a predetermineddilution (step size ofO10) of test compounds
or DMSO.Cells were incubated for 72 hr at 37Cand 4.5%CO2 andwere after-
ward treated with the CellTiter 96 AQueous Non-Radioactive Cell Proliferation
Assay reagent (Promega) according to the manufacturer’s instructions, and
absorbance of the samples was measured at 490 nm using a SaFire II micro-
plate reader (Tecan). Dose response curves over 5 logs of drug concentration
were finally obtained. All MTS cell viability assays were performed in duplicate,
and each experimentwas repeated at least five times. Data pointswere fitted in
GraphPad Prism (GraphPad software) using a four-parameter dose response
model. The mean IC50 values and according SD were determined using the
IC50 values obtained from each individual experiment.
Apoptosis and cell death following 12 hr incubation with the compounds or
DMSO (control) were measured with the AlexaFluor488 Annexin V/Dead Cell
Apoptosis Kit (Life Technologies). Briefly 2 3 105 cells were incubated
overnight with test compounds, carrier (DMSO), and/or the apoptosis inhibitor
Q-VD-OPh ((3S)-5-(2,6-Difluorophenoxy)-3-[[(2S)-3-methyl-1-oxo-2-[(2-qui-
nolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid hydrate; Sigma-
Aldrich), and the following morning cells were incubated with AlexaFluor488
conjugated Annexin V and propidium iodide (PI) according to the manufac-
turer’s instructions. Samples were then analyzed using the green and red
fluorescence with a FACSCanto II flow cytometer (BD Biosciences) and the
FACSDiva software (BD Biosciences).114 Chemistry & Biology 22, 107–116, January 22, 2015 ª2015 ElsevCell cycle analysis was performed using the BD Cyclotest PLUS (BD Biosci-
ences) kit. Cells were incubated for 24 hr with test compounds and harvested
using standard protocol. Following harvesting, the cells were treated accord-
ing to the manufacturer’s instructions, and the DNA content was determined
by measuring PI fluorescence with the FACSCanto II flow cytometer and
FACSDiva software. For both experiments, averages and SDs were calculated
using the data of each individual experiment, and significance was determined
using an unpaired two-tailed Student’s t test taking into account the F values
for equal or unequal variance.
Western Blot Analysis
Western blotting was performed according to standard protocol. In short,
Jurkat cells were seeded at 0.73 106 cells/ml in 24-well plates and incubated
with compound for 16 hr. Cells were then collected at 4003 g andwashedwith
ice-cold PBS. Supernatant was removed, and cells were lysed in lysis buffer
(50 mM Tris-HCl, 50 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100, and 1X halt
protease inhibitor; Thermo Fisher Scientific) for 1 hr on ice (203 106 cells/mL).
Whole-cell lysates were then cleared by brief centrifugation. Protein lysates
were denatured and subsequently resolved by SDS-PAGE and transferred
to a Hybond-P polyvinylidene fluoride (PVDF) membrane (GE Healthcare).
Membranes were incubated for 1 hr at room temperature in blocking buffer
(8%w/v nonfat dry milk in PBS containing 0.05% v/v Tween-20) and thereafter
incubated for 12 hr at 4C in PBS containing 0.05% v/v Tween-20 with primary
antibodies raised against poly [ADP-ribose] polymerase 1 (PARP-1) (sc-8007;
Santa Cruz Biotechnology), caspase-3 (sc-271028; Santa Cruz Biotech-
nology), CRM1/XPO1 (sc-74454; Santa Cruz Biotechnology), or b-tubulin
(ab6046; Abcam). After washing, the membranes were incubated with goat
antimouse or antirabbit IgG horseradish peroxidase-conjugated secondary
antibody (sc-2005; sc-2004; Santa Cruz Biotechnology) in PBS containing
0.05% v/v Tween-20 for 20 min at room temperature. Subsequently, the
membranes were washed extensively, and proteins were detected by chemi-
luminescence on a Chemidoc MP system (Bio-Rad) after the addition of a
luminol/peroxide solution (Thermo Fisher Scientific).
Immunofluorescence Staining and Confocal Fluorescence
Microscopy
Cells were treated with compound or carrier for 4–16 hr. Cells were harvested
at 4003 g, washed in PBS, and transferred into an eight-well chambered Nunc
Lab-Tek Coverglass, which had been pretreated with 0.1% (w/v) poly-L-lysine
(Sigma). The cells were allowed to adhere to the slides and were carefully
washed with PBS. Cells were then fixed with 4% paraformaldehyde, washed,
and permeabilized. Further treatment was performed according to standard
immunofluorescence procedures, and cell nuclei were counterstained with
DAPI. Employed antibodies included rabbit antihuman RanBP1 (Ab97659;
Abcam), rabbit antihuman CRM1/XPO1 (sc-5595; Santa Cruz Biotechnology),
and goat antirabbit IgG conjugated to Alexa Fluor 488 (A11008; Invitrogen). All
images were collected with a Leica TCS SP5 confocal microscope employing
a HCX PL APO 633 (NA 1.2)/water immersion objective. Alexa Fluor 488 was
detected using the excitation line of 488 nm (Argon Laser), and DAPI was
detected using the excitation line of 405 nm (pulsed diode laser). Blue emission
was detected between 410 and 480 nm, and green emission was detected
between 493 and 565 nm.
For quantification of the cellular XPO1 protein content, WT or XPO1C528S
cells were cultured in four different wells of a chambered coverglass in a
randomized manner and then stained for XPO1 as described above. Each
well was imaged three times at different positions in a random order. The
experiment was repeated two times on different dates. The fluorescence in
the green channel was quantified on a per-cell basis employing the Imaris
v.7.6.5 image analysis software (Bitplane). The mean pixel intensity per cell
values were normalized to compare different experiments. For WT and
XPO1C528S cells, 2,269 and 1,866 cells were analyzed, respectively. Statistical
significance was determined with an unpaired two-tailed Student’s t test.
For the colocalization experiments, HeLa cells were transfected with the
respective plasmids and monitored 1 day after transfection using the above
described confocal microscope setup. XPO1 and Rev were visualized by im-
aging the BFP and YFP tags using 405 nm (BFP) or 488 nm (YFP) excitation
lines. Emission was detected between 410 and 480 nm and 505 and
600 nm, respectively.ier Ltd All rights reserved
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For pull down of XPO1 out of Jurkat cells using KPT-9058, 103 106 cells were
incubated for 1.5 hr with 1 mM compound and subsequently extensively
washed in ice-cold PBS. Cell pellets were lysed on ice in radioimmunoprecipi-
tation assay (RIPA) buffer (Sigma-Aldrich) supplemented with 13 HALT prote-
ase inhibitors (Thermo Scientific), cleared from debris by centrifugation at
20,000 3 g for 10 min at 4C. Extracts were allowed to bind to Dynabeads
MyOne Streptavidin T1 (Life Technologies) by rotating overnight at 4C.
Following incubation the beads were extensively washed in modified RIPA
buffer (50 mM Tris-HCl [pH 7.8], 150 mM NaCl, 1% NP-40 [IGEPAL CA-630],
0.1% sodium deoxycholate, 1 mM EDTA), and proteins were eluted by boiling
samples for 10 min in SDS sample buffer. Eluted proteins were separated by
SDS-PAGE and transferred to a Hybond-P PVDF membrane (GE Healthcare),
and XPO1 and b-tubulin were analyzed by western blot as described above.
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